Plain-English translation of NCT06006650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether pembrolizumab, an immunotherapy drug that helps your immune system fight cancer, works better when combined with chemotherapy before surgery for esophageal cancer. Researchers want to compare this new combination approach to standard chemotherapy alone. All participants will also receive additional immunotherapy after surgery to help prevent the cancer from returning.
Esophageal cancer is serious, and current chemotherapy before surgery only helps some patients. Doctors hope that adding this immunotherapy medication will help more patients achieve better results and improve survival.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three treatment plans. All involve three cycles of chemotherapy (given intravenously every three weeks), followed by surgery about three weeks later. After surgery, you would receive 16 additional cycles of immunotherapy medication. Some participants receive the new immunotherapy combined with chemotherapy before surgery, while others receive chemotherapy alone. Throughout the trial, you will have blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China